## Sybren L Meijer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5723411/publications.pdf

Version: 2024-02-01

156	6,146	38 h-index	72
papers	citations		g-index
159	159	159	8093
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Human type $1$ innate lymphoid cells accumulate in inflamed mucosal tissues. Nature Immunology, 2013, 14, 221-229.	7.0	868
2	Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia. JAMA - Journal of the American Medical Association, 2014, 311, 1209.	3.8	545
3	Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut, 2015, 64, 700-706.	6.1	241
4	Remission of Barrett's Esophagus With Early Neoplasia 5 Years After Radiofrequency Ablation With Endoscopic Resection: A Netherlands Cohort Study. Gastroenterology, 2013, 145, 96-104.	0.6	237
5	Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncology, The, 2018, 19, 965-974.	5.1	211
6	Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clinical Cancer Research, 2021, 27, 3351-3359.	3.2	143
7	Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus. Gastroenterology, 2017, 152, 564-570.e4.	0.6	133
8	The immunology of the vermiform appendix: a review of the literature. Clinical and Experimental Immunology, 2016, 186, 1-9.	1.1	130
9	Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2237-2242.	3.3	128
10	Computer-aided detection of early Barrett's neoplasia using volumetric laser endomicroscopy. Gastrointestinal Endoscopy, 2017, 86, 839-846.	0.5	117
11	Deep learning for automatic Gleason pattern classification for grade group determination of prostate biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 77-83.	1.4	94
12	Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression toÂNeoplasia. Gastroenterology, 2017, 152, 993-1001.e1.	0.6	91
13	The Link between the Appendix and Ulcerative Colitis: Clinical Relevance and Potential Immunological Mechanisms. American Journal of Gastroenterology, 2016, 111, 163-169.	0.2	84
14	Prognostic value of estrogen receptor $\hat{l}_{\pm}$ and progesterone receptor conversion in distant breast cancer metastases. Cancer, 2012, 118, 4929-4935.	2.0	81
15	Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nature Communications, 2016, 7, 12158.	5.8	<b>7</b> 5
16	Vaccination of Women with Metastatic Breast Cancer, Using a Costimulatory Gene (CD80)-Modified, HLA-A2-Matched, Allogeneic, Breast Cancer Cell Line: Clinical and Immunological Results. Human Gene Therapy, 2003, 14, 1117-1123.	1.4	74
17	Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study. Endoscopy, 2013, 45, 516-525.	1.0	70
18	microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients. Gastroenterology, 2018, 155, 784-798.	0.6	70

#	Article	IF	CITATIONS
19	Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. International Journal of Cancer, 2020, 146, 1445-1456.	2.3	67
20	Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188386.	3.3	67
21	Identification of volumetric laser endomicroscopy features predictive for early neoplasia in Barrett's esophagus using high-quality histological correlation. Gastrointestinal Endoscopy, 2017, 85, 918-926.e7.	0.5	66
22	Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. BMC Cancer, 2019, 19, 662.	1.1	62
23	Development of Fibrosis in Acute and Longstanding Ulcerative Colitis. Journal of Crohn's and Colitis, 2015, 9, 966-972.	0.6	61
24	Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. Journal of Translational Medicine, 2015, 13, 115.	1.8	60
25	The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus. Gut, 2015, 64, 49-56.	6.1	60
26	Deficiency of Nuclear Receptor Nur77 Aggravates Mouse Experimental Colitis by Increased NFκB Activity in Macrophages. PLoS ONE, 2015, 10, e0133598.	1.1	60
27	Loss of intestinal sympathetic innervation elicits an innate immune driven colitis. Molecular Medicine, 2019, 25, 1.	1.9	59
28	Bcl-2 is a critical mediator of intestinal transformation. Nature Communications, 2016, 7, 10916.	5.8	55
29	Detection of buried Barrett's glands after radiofrequency ablation with volumetric laser endomicroscopy. Gastrointestinal Endoscopy, 2016, 83, 80-88.	0.5	52
30	Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Research, 2012, 14, R93.	2.2	50
31	Circumferential Balloon-based Radiofrequency Ablation of Barrett's Esophagus With Dysplasia Can Be Simplified, yet Efficacy Maintained, by Omitting the Cleaning Phase. Clinical Gastroenterology and Hepatology, 2013, 11, 491-498.e1.	2.4	50
32	Role of omentectomy as part of radical surgery for gastric cancer. British Journal of Surgery, 2016, 103, 1497-1503.	0.1	50
33	Neuronal control of experimental colitis occurs via sympathetic intestinal innervation. Neurogastroenterology and Motility, 2018, 30, e13163.	1.6	50
34	Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 394-403.	3.3	45
35	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study. Journal of Clinical Oncology, 2020, 38, 462-471.	0.8	44
36	Feasibility of laser marking in Barrett's esophagus with volumetric laser endomicroscopy: first-in-man pilot study. Gastrointestinal Endoscopy, 2017, 86, 464-472.	0.5	42

#	Article	lF	Citations
37	Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma. Ecological Management and Restoration, 2014, 27, 380-387.	0.2	41
38	Effects of Autofluorescence Imaging on Detection and Treatment of Early Neoplasia in Patients With Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 774-781.	2.4	39
39	Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett's oesophagus. Gut, 2016, 65, 907-913.	6.1	39
40	Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study. Gut, 2016, 65, 1602-1610.	6.1	39
41	Histopathologist features predictive of diagnostic concordance at expert level among a large international sample of pathologists diagnosing Barrett's dysplasia using digital pathology. Gut, 2020, 69, 811-822.	6.1	39
42	Aberrant TP53 detected by combining immunohistochemistry and DNAâ€FISH improves Barrett's esophagus progression prediction: A prospective followâ€up study. Genes Chromosomes and Cancer, 2015, 54, 82-90.	1.5	38
43	Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Annals of Surgery, 2021, 274, 1009-1016.	2.1	38
44	Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction. Annals of Surgery, 2016, 264, 847-853.	2.1	37
45	Efficacy of the CryoBalloon Focal Ablation System for the eradication of dysplastic Barrett's esophagus islands. Endoscopy, 2017, 49, 169-175.	1.0	37
46	Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior. Breast Cancer Research and Treatment, 2019, 174, 649-659.	1.1	37
47	Orally delivered $\hat{l}^2$ -glucans aggravate dextran sulfate sodium (DSS)-induced intestinal inflammation. Nutrition Research, 2015, 35, 1106-1112.	1.3	36
48	Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer. Annals of Surgery, 2017, 265, 356-362.	2.1	34
49	Automated Detection and Grading of Non–Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. American Journal of Pathology, 2020, 190, 1483-1490.	1.9	34
50	Identification of Tumor-Specific Antibodies in Patients With Breast Cancer Vaccinated With Gene-Modified Allogeneic Tumor Cells. Journal of Immunotherapy, 2003, 26, 163-170.	1.2	32
51	Endoscopic management and followâ€up of patients with a submucosal esophageal adenocarcinoma. United European Gastroenterology Journal, 2018, 6, 669-677.	1.6	31
52	Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease. PLoS ONE, 2018, 13, e0190999.	1.1	30
53	Adoptive Cellular Therapy With Tumor Vaccine Draining Lymph Node Lymphocytes After Vaccination With HLA-B7/β2-Microglobulin Gene-Modified Autologous Tumor Cells. Journal of Immunotherapy, 2002, 25, 359-372.	1.2	29
54	Needle-based confocal laser endomicroscopy for real-time diagnosingÂand staging of lung cancer. European Respiratory Journal, 2019, 53, 1801520.	3.1	29

#	Article	IF	Citations
55	HER2 gene amplification in patients with breast cancer with equivocal IHC results. Journal of Clinical Pathology, 2011, 64, 1069-1072.	1.0	28
56	Improved diagnostic stratification of digitised Barrett's oesophagus biopsies by p53 immunohistochemical staining. Histopathology, 2018, 72, 1015-1023.	1.6	28
57	A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas. Scientific Reports, 2018, 8, 13281.	1.6	28
58	ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. Oncotarget, 2016, 7, 10243-10254.	0.8	27
59	Pathological Findings in Gynecomastia. Annals of Plastic Surgery, 2015, 74, 163-166.	0.5	26
60	A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma. Ecological Management and Restoration, 2019, 32, .	0.2	26
61	Regression of a Mammary Adenocarcinoma in STAT6â°'/â°' Mice Is Dependent on the Presence of STAT6-Reactive T Cells. Journal of Immunology, 2003, 170, 2014-2021.	0.4	24
62	Preoperative Chemoradiation Therapy in Combination With Panitumumab for Patients With Resectable Esophageal Cancer: The PACT Study. International Journal of Radiation Oncology Biology Physics, 2014, 90, 190-196.	0.4	24
63	Histopathology: ditch the slides, because digital and 3D are on show. World Journal of Urology, 2018, 36, 549-555.	1.2	23
64	Chemoradiation induces epithelialâ€ŧoâ€mesenchymal transition in esophageal adenocarcinoma. International Journal of Cancer, 2019, 145, 2792-2803.	2.3	23
65	Tissue Systems Pathology Test Objectively Risk Stratifies Barrett's Esophagus Patients With Low-Grade Dysplasia. American Journal of Gastroenterology, 2021, 116, 675-682.	0.2	23
66	Targeted therapy for advanced esophagogastric adenocarcinoma. Critical Reviews in Oncology/Hematology, 2014, 90, 68-76.	2.0	22
67	Volumetric laser endomicroscopy in Barrett's esophagus: a feasibility study on histological correlation. Ecological Management and Restoration, 2016, 29, 505-512.	0.2	22
68	Induction of Circulating Tumor-reactive CD8+ T Cells After Vaccination of Melanoma Patients With the gp100209-2M Peptide. Journal of Immunotherapy, 2007, 30, 533-543.	1.2	21
69	Is it justified to ablate flat-type esophageal squamous cancer? An analysis of endoscopic submucosal dissection specimens of lesions meeting the selection criteria of radiofrequency studies.  Gastrointestinal Endoscopy, 2014, 80, 995-1002.	0.5	20
70	Effects of Dietary Plant Sterols and Stanol Esters with Low- and High-Fat Diets in Chronic and Acute Models for Experimental Colitis. Nutrients, 2015, 7, 8518-8531.	1.7	20
71	A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial Journal of Clinical Oncology, 2019, 37, 4045-4045.	0.8	20
72	Third-generation autofluorescence endoscopy for the detection of early neoplasia in Barrett's esophagus: a pilot study. Ecological Management and Restoration, 2014, 27, 276-284.	0.2	19

#	Article	IF	CITATIONS
73	Real-Time Optical Biopsy of Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2016, 194, e10-e11.	2.5	19
74	Long-term follow-up results of stepwise radical endoscopic resection for Barrett's esophagus with early neoplasia. Gastrointestinal Endoscopy, 2018, 87, 77-84.	0.5	19
75	Strategies for managing multi-patient 3D mass spectrometry imaging data. Journal of Proteomics, 2019, 193, 184-191.	1.2	19
76	Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. World Journal of Gastroenterology, 2012, 18, 4288.	1.4	18
77	Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. Breast Cancer Research and Treatment, 2015, 152, 247-252.	1.1	18
78	Pilot-study on the feasibility of sentinel node navigation surgery in combination with thoracolaparoscopic lymphadenectomy without esophagectomy in early esophageal adenocarcinoma patients. Ecological Management and Restoration, 2017, 30, 1-8.	0.2	18
79	Treatment strategies in recurrent esophageal or junctional cancer. Ecological Management and Restoration, 2017, 30, 1-9.	0.2	18
80	Three-dimensional histopathological reconstruction of bladder tumours. Diagnostic Pathology, 2019, 14, 25.	0.9	18
81	Analysis of metastases rates during follow-up after endoscopic resection of early "high-risk― esophageal adenocarcinoma. Gastrointestinal Endoscopy, 2022, 96, 237-247.e3.	0.5	18
82	Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes. Annals of Surgical Oncology, 2015, 22, 766-771.	0.7	17
83	Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy. British Journal of Surgery, 2016, 103, 1658-1664.	0.1	17
84	The dynamics of HER2 status in esophageal adenocarcinoma. Oncotarget, 2018, 9, 26787-26799.	0.8	17
85	Distribution of lymph node metastases in esophageal adenocarcinoma after neoadjuvant chemoradiation therapy: a prospective study. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 4347-4357.	1.3	16
86	Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. Gastric Cancer, 2020, 23, 579-590.	2.7	16
87	Inhibition of miR-142-5P ameliorates disease in mouse models of experimental colitis. PLoS ONE, 2017, 12, e0185097.	1.1	16
88	Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer. Gastric Cancer, 2022, 25, 906-915.	2.7	15
89	Pathologic Findings in Primary Capsulectomy Specimens: Analysis of 2531 Patients. Aesthetic Surgery Journal, 2014, 34, 714-718.	0.9	13
90	Digital microscopy as valid alternative to conventional microscopy for histological evaluation of Barrett's esophagus biopsies. Ecological Management and Restoration, 2017, 30, 1-7.	0.2	13

#	Article	IF	Citations
91	Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Endoscopy, 2022, 54, 109-117.	1.0	13
92	Extending treatment criteria for Barrett's neoplasia: results of a nationwide cohort of 138 endoscopic submucosal dissection procedures. Endoscopy, 2022, 54, 531-541.	1.0	13
93	Disseminated bread yeast fungaemia in a baker's wife with acute myeloid leukaemia. British Journal of Haematology, 2012, 158, 298-298.	1.2	12
94	A singleâ€step sizing and radiofrequency ablation catheter for circumferential ablation of Barrett's esophagus: Results of a pilot study. United European Gastroenterology Journal, 2018, 6, 990-999.	1.6	12
95	Machine learning for grading and prognosis of esophageal dysplasia using mass spectrometry and histological imaging. Computers in Biology and Medicine, 2021, 138, 104918.	3.9	12
96	Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. Cellular Immunology, 2004, 227, 93-102.	1.4	11
97	Genetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing Cholangitis. Gastroenterology Research and Practice, 2016, 2016, 1-9.	0.7	11
98	What Makes an Expert Barrett's Histopathologist?. Advances in Experimental Medicine and Biology, 2016, 908, 137-159.	0.8	11
99	Feasibility of Optical Coherence Tomography (OCT) for Intra-Operative Detection of Blood Flow during Gastric Tube Reconstruction. Sensors, 2018, 18, 1331.	2.1	11
100	Adherence to preâ€set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett's esophagus biopsies – towards digital review of Barrett's esophagus. United European Gastroenterology Journal, 2019, 7, 889-896.	1.6	11
101	Prospective development and validation of a volumetric laser endomicroscopy computer algorithm for detection of Barrett's neoplasia. Gastrointestinal Endoscopy, 2021, 93, 871-879.	0.5	11
102	Feasibility of sentinel node navigated surgery in high-risk T1b esophageal adenocarcinoma patients using a hybrid tracer of technetium-99Âm and indocyanine green. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 2671-2679.	1.3	11
103	Tumorâ€immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. Journal of Pathology, 2022, 256, 282-296.	2.1	11
104	Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo. BMC Gastroenterology, 2012, 12, 172.	0.8	10
105	Development of benchmark quality criteria for assessing wholeâ€endoscopy Barrett's esophagus biopsy cases. United European Gastroenterology Journal, 2018, 6, 830-837.	1.6	10
106	Dietary Curdlan Enhances Bifidobacteria and Reduces Intestinal Inflammation in Mice. Nutrients, 2021, 13, 1305.	1.7	10
107	Barrett's esophagus surveillance in a prospective Dutch multiâ€center communityâ€based cohort of 985 patients demonstrates low risk of neoplastic progression. United European Gastroenterology Journal, 2021, 9, 929-937.	1.6	10
108	Quantitative attenuation analysis for identification of early Barrett's neoplasia in volumetric laser endomicroscopy. Journal of Biomedical Optics, 2017, 22, 086001.	1.4	10

#	Article	IF	CITATIONS
109	Immunological Monitoring of Patients with Melanoma After Peptide Vaccination Using Soluble Peptide/HLA-A2 Dimer Complexes. Journal of Immunotherapy, 2004, 27, 48-59.	1.2	9
110	Fluorescence spectroscopy incorporated in an Optical Biopsy System for the detection of early neoplasia in Barrett's esophagus. Ecological Management and Restoration, 2015, 28, 345-351.	0.2	9
111	Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis. Scientific Reports, 2017, 7, 3135.	1.6	9
112	A genomic biomarker-based model for cancer risk stratification of non-dysplastic Barrett's esophagus patients after extended follow up; results from Dutch surveillance cohorts PLoS ONE, 2020, 15, e0231419.	1,1	9
113	Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes. Human Pathology, 2021, 116, 94-101.	1.1	9
114	Optimized endoscopic autofluorescence spectroscopy for the identification of premalignant lesions in Barrett's oesophagus. European Journal of Gastroenterology and Hepatology, 2013, 25, 1442-1449.	0.8	8
115	Miltefosine Suppresses Inflammation in a Mouse Model of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 1.	0.9	8
116	Evaluation of collimated polarized light imaging for real-time intraoperative selective nerve identification in the human hand. Biomedical Optics Express, 2017, 8, 4122.	1.5	8
117	Improved Clinical and Survival Outcomes After Esophagectomy for Cancer Over 25 Years. Annals of Thoracic Surgery, 2022, 114, 1118-1126.	0.7	8
118	237 Feasibility of a Computer Algorithm for Detection of Early Barrett's Neoplasia Using Volumetric Laser Endomicroscopy. Gastroenterology, 2016, 150, S56.	0.6	7
119	Simultaneous use of endoscopic resection and radiofrequency ablation is not safe in an esophageal porcine model. Ecological Management and Restoration, 2015, 28, 25-31.	0.2	6
120	Tu1201 How Good Are Experts in Identifying Endoscopically Visible Early Barrett's Neoplasia on in vivo Volumetric Laser Endomicroscopy?. Gastrointestinal Endoscopy, 2016, 83, AB573.	0.5	6
121	Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). Cancers, 2019, 11, 827.	1.7	6
122	Multicenter study on the diagnostic performance of multiframe volumetric laser endomicroscopy targets for Barrett's esophagus neoplasia with histopathology correlation. Ecological Management and Restoration, 2020, 33, .	0.2	6
123	The Amsterdam ReBus progressor cohort: identification of 165 Barrett's surveillance patients who progressed to early neoplasia and 723 nonprogressor patients. Ecological Management and Restoration, 2019, 32, .	0.2	5
124	Fluorescence characteristics of human Barrett tissue specimens grafted on chick chorioallantoic membrane. Lasers in Medical Science, 2016, 31, 137-144.	1.0	4
125	Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study. Biomedical Optics Express, 2018, 9, 4196.	1.5	4
126	Results of a two-phased clinical study evaluating a new multiband mucosectomy device for early Barrett's neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 2864-2872.	1.3	4

#	Article	IF	CITATIONS
127	Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study Journal of Clinical Oncology, 2018, 36, 4057-4057.	0.8	4
128	miR-511 Deficiency Protects Mice from Experimental Colitis by Reducing TLR3 and TLR4 Responses via WD Repeat and FYVE-Domain-Containing Protein 1. Cells, 2022, 11, 58.	1.8	4
129	A Full Stomach. Gastroenterology, 2014, 147, 974-976.	0.6	3
130	37 Quantitative Analysis of Volumetric Laser Endomicroscopy Images With Histological Correlation of Ex-Vivo Endoscopic Resection Specimens of Barrett's Esophagus With and Without Early Neoplasia. Gastroenterology, 2014, 146, S-10.	0.6	3
131	Efficacy and safety of a novel submucosal lifting gel used for endoscopic submucosal dissection: a study in a porcine model. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 2651-2660.	1.3	3
132	Su2076 How Good are Experts in Identifying Early Barrett's Neoplasia in Endoscopic Resection Specimens Using Volumetric Laser Endomicroscopy?. Gastroenterology, 2016, 150, S628.	0.6	3
133	Lymph node metastases near the celiac trunk should be considered separately from other nodal metastases in patients with cancer of the esophagus or gastroesophageal junction after neoadjuvant treatment and surgery. Journal of Thoracic Disease, 2018, 10, 1511-1521.	0.6	3
134	Radiofrequency vapor ablation for Barrett's esophagus: feasibility, safety and proof of concept in a stepwise study with in vitro, animal, and the first in-human application. Endoscopy, 2021, 53, 1162-1168.	1.0	3
135	Significant variation in histopathological assessment of endoscopic resections for Barrett's neoplasia suggests need for consensus reporting: propositions for improvement. Ecological Management and Restoration, 2021, 34, .	0.2	3
136	Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 114, 54-65.	1.1	3
137	Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma. United European Gastroenterology Journal, 2021, 9, 1066-1073.	1.6	3
138	The prognostic value of a modified tumor regression grade after neoadjuvant chemoradiotherapy and resection of esophageal carcinoma Journal of Clinical Oncology, 2015, 33, 4066-4066.	0.8	3
139	Ex-vivo study in nephroureterectomy specimens defining the role of 3-D upper urinary tract visualization using optical coherence tomography and endoluminal ultrasound. Journal of Medical Imaging, 2018, 5, 1.	0.8	3
140	A phase lb/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211091.	1.4	3
141	Impact of increasing lymph node yield on staging, morbidity and survival after esophagectomy for esophageal adenocarcinoma. European Journal of Surgical Oncology, 2023, 49, 89-96.	0.5	3
142	420 Quantitative Analysis of Volumetric Laser Endomicroscopy of Histologically Correlated Images Potentially Identifies Early Neoplasia in Barrett's Esophagus. Gastroenterology, 2015, 148, S-91.	0.6	2
143	Microscopic tumor spread beyond (echo)endoscopically determined tumor borders in esophageal cancer. Radiation Oncology, 2019, 14, 219.	1.2	2
144	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers, 2021, 13, 839.	1.7	2

#	Article	IF	CITATIONS
145	Multicenter phase II study combining panitumumab with chemoradiation followed by surgery for patients with operable esophageal cancer (PACT-study) Journal of Clinical Oncology, 2012, 30, 4094-4094.	0.8	2
146	The SpaTemp cohort: 168 nondysplastic Barrett's esophagus surveillance patients with and without progression to early neoplasia to evaluate the distribution of biomarkers over space and time. Ecological Management and Restoration, 2021, 34, .	0.2	1
147	Survival after pathologic complete response in patients with cancer of the esophagus or gastroesophageal junction Journal of Clinical Oncology, 2014, 32, e15084-e15084.	0.8	1
148	The prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and esophagectomy Journal of Clinical Oncology, 2015, 33, 4058-4058.	0.8	1
149	FOXO transcriptional activity is associated with response to chemoradiation in EAC. Journal of Translational Medicine, 2022, 20, 183.	1.8	1
150	Chapter 2: Role of pathologic confirmation for Barrett′s esophagus and dysplasia. Techniques in Gastrointestinal Endoscopy, 2018, 20, 62-69.	0.3	0
151	O108 GENOMIC BIOMARKERS FOR CANCER RISK IN BARRETT'S ESOPHAGUS: AN UPDATE ON THE LONGITUDINAL DUTCH BARRETT'S ESOPHAGUS COHORT. Ecological Management and Restoration, 2019, 32, .	0.2	0
152	P032 MiR-511 deficiency aggravates T cell transfer colitis in mice. Journal of Crohn's and Colitis, 2021, 15, S147-S147.	0.6	0
153	Immunological and Molecular Analysis of the Sentinel Lymph Node: a Potential Approach to Predict Outcome, Tailor Therapy, and Optimize Parameters for Tumor Vaccine Development. Journal of Clinical Pharmacology, 2001, 41, 81-94.	1.0	0
154	The role of statines in the treatment of esophageal cancer patients Journal of Clinical Oncology, 2014, 32, e15083-e15083.	0.8	0
155	Treatment strategies in recurrent esophageal or junctional cancer after neoadjuvant therapy followed by esophagectomy Journal of Clinical Oncology, 2015, 33, e15024-e15024.	0.8	0
156	Multicenter feasibility study of chemoradiation, trastuzumab and pertuzumab in resectable HER2+ esophageal carcinoma: The TRAP study Journal of Clinical Oncology, 2016, 34, TPS4142-TPS4142.	0.8	O